Masseteric Nerve Transfer for Facial Paralysis Secondary to Parotid Malignancy: A Retrospective Case Series.
Bastien A Valencia-SanchezRyan J LiMark K WaxJohn NgPeter E AndersenMyriam LoyoPublished in: Facial plastic surgery & aesthetic medicine (2023)
Background: The objective outcomes of masseteric nerve transfer in the setting of parotid malignancy are unclear. Objective: To measure objective facial reanimation outcomes of masseteric nerve transfer in patients with parotid malignancy who underwent parotidectomy with facial nerve resection. Materials and Methods: Retrospective review of patients who underwent masseteric nerve transfer for facial paralysis secondary to parotid malignancy was carried out at a tertiary referral hospital from August 2017 to November 2021. Objective facial reanimation outcomes were analyzed using Emotrics. Minimal follow-up of 6 months was required for inclusion. Results: Eight patients (five males) with a median age of 75.5 years (range 53-91) met inclusion criteria. Fifty percent had metastatic squamous cell carcinoma, and 50% had primary parotid malignancy. Five patients underwent concomitant cancer resection with facial nerve reconstruction. Seven patients received postoperative adjuvant radiotherapy. After reinnervation, patients had improved oral commissure excursion (from 1.51 mm ±1.27 to 3.77 mm ±1.81; p < 0.01) and facial symmetry during smile. Conclusion: In this study, masseteric nerve transfer enhanced oral commissure excursion and facial symmetry during smile in patients with parotid malignancy and facial nerve resection.
Keyphrases
- end stage renal disease
- squamous cell carcinoma
- ejection fraction
- newly diagnosed
- chronic kidney disease
- peritoneal dialysis
- early stage
- small cell lung cancer
- primary care
- patient reported outcomes
- peripheral nerve
- metabolic syndrome
- insulin resistance
- skeletal muscle
- patient reported
- lymph node metastasis
- radiation induced
- papillary thyroid
- squamous cell